Plant Comparison
Tansy vs Common coltsfoot
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Tansy and Common coltsfoot: both belong to the Asteraceae family; they share 3 indicated uses (arthritis / joint pain, inflammation (general), skin irritation); 1 pharmacological action in common.
Evidence face-off — shared uses
| Condition | Tansy | Common coltsfoot | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 1/10 | 1/10 | Comparable evidence |
| Inflammation (general) | 1/10 | 2/10 | Comparable evidence |
| Skin irritation | 1/10 | 1/10 | Comparable evidence |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Thujone is the neurotoxic, safety-limiting constituent responsible for tansy's real internal-use toxicity.
Contribute to the plant's bitter taste and antimicrobial activity.
Hepatotoxic constituents that are the central safety concern for this plant; regulatory limits and PA-controlled/PA-reduced products exist specifically because of these compounds.
Demulcent polysaccharide contributing to the traditional soothing action on irritated airways.
Pharmacological Actions
Traditional & Indicated Uses
inferred from anti-inflammatory action
inferred from digestive action
inferred from antimicrobial action
inferred from anti-inflammatory action
inferred from antispasmodic action
inferred from antispasmodic action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from sedative action
Safety, Cautions & Contraindications
CAUTION: Tansy is considered toxic in medicinal doses and is NOT recommended for internal use. Thujone can cause convulsions, liver and kidney damage. Contraindicated in pregnancy (uterotonic and abortifacient). External use (as insect repellent) is generally safe. For information and historical reference only — do not use internally.
Duke (2002) rates tansy as ++ but emphasizes important safety concerns. The plant contains thujone (a neurotoxic ketone) and camphor, making it potentially toxic with internal use. Documented activities include emmenagogue, abortifacient (score 1), and insecticide. Duke strongly cautions against internal use except under professional supervision, noting that historical cases of tansy poisoning have resulted in convulsions and death. Topical use as an insect repellent is safer but should still avoid prolonged skin contact due to the essential oil's sensitizing potential. Strictly contraindicated in pregnancy (Duke, 2002).
Safety notes (contraindications, interactions, pregnancy/lactation notes, adverse effects, dose-duration cautions) Important: Coltsfoot naturally contains pyrrolizidine alkaloids (PAs)—plant chemicals that can damage the liver and may increase cancer risk with enough exposure (EMA, 2021; Kopp et al., 2020).
Because of this, European regulators set very strict limits for PA exposure from herbal products (EMA, 2021).
Many safety-focused herbal references recommend avoiding homemade/internal coltsfoot use, unless the product is specifically made to be PA-controlled / PA-reduced (EMA, 2021).
Avoid internal use if you are pregnant or breastfeeding, have liver disease, or for children—these groups are treated as “sensitive” in PA risk guidance (EMA, 2021).
Medication caution: if you take medicines that stress the liver (some prescription drugs can), it’s extra important to avoid unregulated PA exposure (general PA risk logic; consult a clinician) (EMA, 2021).
Topical use may still carry PA considerations; EMA discusses limits and recommends use only on intact skin for PA-containing products (EMA, 2021).
Duke (2002) provides clinical support (score 2) for coltsfoot's anti-inflammatory and expectorant effects, explaining its traditional use in bronchitis and coughs. However, the plant contains hepatotoxic pyrrolizidine alkaloids (PAs), and Duke notes a carcinogenic score (1) — a critical safety concern. Commission E has placed restrictions on coltsfoot use, recommending maximum internal use of 4–6 weeks per year and avoiding use in pregnancy, lactation, and in children under 12. Duke rates its overall safety as low (+) and emphasizes that preparations free of PAs are preferred (Duke, 2002).
External Ids
Botanical Description
Aromatic perennial herb (Asteraceae), 50-120 cm tall, with erect, reddish, ridged stems. Leaves are finely divided, fern-like and strongly camphor-scented. Flat-topped clusters of small, yellow, button-like flower heads lack ray florets (petals).[11]
Low perennial herb notable for flowering before its leaves appear: solitary, bright yellow, dandelion-like flower heads emerge on scaly pinkish stalks in very early spring, followed later by large, hoof-shaped (heart-shaped with angular teeth), white-woolly-backed leaves arising directly from the creeping rhizome.[11]
Habitat
Native to Europe and temperate Asia, widely naturalised elsewhere; grows on roadsides, waste ground, riverbanks and disturbed grassland.[11]
Grows on disturbed, damp or clay-rich waste ground, riverbanks, railway embankments and bare soil; native to Europe, North Africa and temperate Asia and naturalised in North America.[11]
Harvesting
Flowering aerial parts are cut in summer, when in full flower, and dried for external/historical use; given this plant's real toxicity (thujone content) at internal doses, this record does not recommend or describe internal harvesting for medicinal consumption.[11]
Flowers are gathered in very early spring before the leaves appear; leaves are gathered later in the season once expanded. Given the plant's pyrrolizidine alkaloid content, harvesting from a positively confirmed patch (not a look-alike) and preferring PA-tested commercial material for internal use is strongly advised.[2]
Traditional Uses
Tansy has a long European history as a strewing herb, insect repellent and, historically, an internal vermifuge and emmenagogue, but its thujone and camphor content make internal medicinal use unsafe by modern standards. Today it is used, with caution, mainly as an external insect repellent; the traditional internal uses are recorded here for historical reference only, not as a recommendation.[11]
Coltsfoot has an ancient European and Chinese tradition, reflected in its Latin name (tussis = cough), as an expectorant and demulcent remedy for coughs, bronchitis and irritated airways; because of its pyrrolizidine alkaloid content, contemporary use is restricted to short courses of PA-controlled preparations under regulatory limits (see contraindications).[1, 2, 12]
Preparations
Commercially prepared, pyrrolizidine-alkaloid-tested extract or syrup, the only form recommended for internal use given the plant's natural PA content.
Dried flower or leaf infused in hot water; traditional but subject to strict duration/PA-content limits under EU herbal regulation.
Dosage
Tansy is NOT recommended for internal use at any dose given its thujone content and documented toxicity (convulsions, liver/kidney damage) - internal use recorded here is for historical reference only. External use (e.g. as an insect repellent) should avoid prolonged skin contact. Educational reference only, not a prescription; strictly avoid in pregnancy.
EU regulatory guidance restricts internal use to PA-controlled preparations. The EMA public statement on unsaturated pyrrolizidine alkaloids records a maximum daily intake for internal use of 1 microgram of PAs for at most 6 weeks per year, or 0.1 microgram per day with no duration limit; for cutaneous use the limits are 100 micrograms for at most 6 weeks per year, or 10 micrograms without a duration limit. Not for use in pregnancy, breastfeeding, or children. Note that these are limits on PA intake, not a herb dose — no EMA monograph exists for Tussilago farfara, so there is no official posology for the herb itself. Educational reference only, not a prescription — consult a qualified practitioner and prefer tested commercial products.
References
Lookalikes Review
Dangerous Lookalikes
References & Sources
- Kowalonek, J., Stachowiak, N., Bolczak, K. and Richert, A (2023) 'Physicochemical and Antibacterial Properties of Alginate Films Containing Tansy (Tanacetum vulgare L.) Essential Oil', Polymers, 15(2), pp. 260. doi:10.3390/polym15020260 Preclinical
https://doi.org/10.3390/polym15020260 - Ak, G., Gevrenova, R., Sinan, K.I., Zengin, G. and others (2021) 'Tanacetum vulgare L. (Tansy) as an effective bioresource with promising pharmacological effects from natural arsenal', Food and Chemical Toxicology, 153, pp. 112268. doi:10.1016/j.fct.2021.112268 Preclinical
https://doi.org/10.1016/j.fct.2021.112268 - Paderin, N.M., Saveliev, Y.N. and Popov, S.V (2020) 'The effect of pectin of tansy, Tanacetum vulgare L., on anxiety and overeating food rich in fats and sugars in mice in modelling binge eating', Voprosy Pitaniia, 89(6), pp. 14-22. doi:10.24411/0042-8833-2020-10074 Preclinical
https://doi.org/10.24411/0042-8833-2020-10074 - Babich, O., Larina, V., Krol, O., Ulrikh, E. and others (2023) 'In Vitro Study of Biological Activity of Tanacetum vulgare Extracts', Pharmaceutics, 15(2), pp. 616. doi:10.3390/pharmaceutics15020616 Preclinical
https://doi.org/10.3390/pharmaceutics15020616 - Puk, K. and Guz, L (2021) 'Parasiticidal effects of Tanacetum vulgare extract against Ichthyophthirius multifiliis', Polish Journal of Veterinary Sciences, 24(1), pp. 159-161. doi:10.24425/pjvs.2021.136805 Preclinical
https://doi.org/10.24425/pjvs.2021.136805 - Roman, H., Niculescu, A.G., Lazar, V. and Mitache, M.M (2023) 'Antibacterial Efficiency of Tanacetum vulgare Essential Oil against ESKAPE Pathogens and Synergisms with Antibiotics', Antibiotics, 12(11), pp. 1635. doi:10.3390/antibiotics12111635 Preclinical
https://doi.org/10.3390/antibiotics12111635 - Sukele, R., Lauberte, L., Kovalcuka, L., Logviss, K. and others (2023) 'Chemical Profiling and Antioxidant Activity of Tanacetum vulgare L. Wild-Growing in Latvia', Plants, 12(10), pp. 1968. doi:10.3390/plants12101968 Preclinical
https://doi.org/10.3390/plants12101968 - Korpinen, R.I., Valimaa, A.L., Liimatainen, J. and Kunnas, S (2021) 'Essential Oils and Supercritical CO2 Extracts of Arctic Angelica, Marsh Labrador Tea and Common Tansy (Tanacetum vulgare)-Chemical Compositions and Antimicrobial Activities', Molecules, 26(23), pp. 7121. doi:10.3390/molecules26237121 Preclinical
https://doi.org/10.3390/molecules26237121 - Jovanovic, M. and Poljacki, M (2003) 'Compositae dermatitis', Medicinski Pregled, 56(1-2), pp. 43-49. doi:10.2298/mpns0302043j Meta-analysis / review
https://doi.org/10.2298/mpns0302043j - Rohloff, J., Mordal, R. and Dragland, S (2004) 'Chemotypical variation of tansy (Tanacetum vulgare L.) from 40 different locations in Norway', Journal of Agricultural and Food Chemistry, 52(6), pp. 1742-1748. doi:10.1021/jf0352430 Preclinical
https://doi.org/10.1021/jf0352430 - Grieve, M (1931) 'A Modern Herbal'. Traditional / reference
https://scholar.google.com/scholar?q=A%20Modern%20Herbal - Kivilaan, A. and Bandurski, R.S (1981) 'The 1879 Beal seed viability experiment', 68(9), pp. 1290--1292. Traditional / reference
https://scholar.google.com/scholar?q=The%201879%20Beal%20seed%20viability%20experiment - Orav, A., Raal, A. and Arak, E (2006) 'Essential oil composition of Tanacetum vulgare L', 20(12), pp. 1129--1142. Traditional / reference
https://scholar.google.com/scholar?q=Essential%20oil%20composition%20of%20Tanacetum%20vulgare%20L - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Washington State Noxious Weed Control Board 'Tansy Ragwort (Senecio jacobaea)'. Available at: https://www.nwcb.wa.gov/weeds/tansy-ragwort Traditional / reference
https://www.nwcb.wa.gov/weeds/tansy-ragwort - Schneider, J. and Tsegaye, Y. and W/Tensae, M. and G/Selassie, S. and Haile, T. and Bane, A. and Ali, A. and Mesfin, G. and Seboxa, T (2012) 'Veno-occlusive liver disease: a case report', Ethiopian Medical Journal, 50 Suppl 2, pp. 47-51. Available at: https://pubmed.ncbi.nlm.nih.gov/22946295/ Clinical study
https://pubmed.ncbi.nlm.nih.gov/22946295/
- Ahmad, I., Kudaibergenova, B., Ahmad, M. and others (2025) 'Coltsfoot (Tussilago farfara L.; Asteraceae): modern methods of extraction, phytochemistry, nanoparticles synthesis, ethnopharmacology, and biological activities', Natural Product Research, pp. 1-20. doi:10.1080/14786419.2025.2548616 Traditional / reference
https://doi.org/10.1080/14786419.2025.2548616 - Chen, S., Dong, L., Quan, H., Zhou, X. and others (2020) 'A review of the ethnobotanical value, phytochemistry, pharmacology, toxicity and quality control of Tussilago farfara L. (coltsfoot)', Journal of Ethnopharmacology, 267, pp. 113478. doi:10.1016/j.jep.2020.113478 Traditional / reference
https://doi.org/10.1016/j.jep.2020.113478 - Feng, J., Zhang, Y., Qin, X., Gao, T. and others (2022) 'Novel Quinic Acid Glycerates from Tussilago farfara Inhibit Polypeptide GalNAc-Transferase', ChemBioChem, 23(3), pp. e202100539. doi:10.1002/cbic.202100539 Preclinical
https://doi.org/10.1002/cbic.202100539 - Zhao, J., Evangelopoulos, D., Bhakta, S., Gray, A.I. and Seidel, V (2014) 'Antitubercular activity of Arctium lappa and Tussilago farfara extracts and constituents', Journal of Ethnopharmacology, 155(1), pp. 796-800. doi:10.1016/j.jep.2014.06.034 Preclinical
https://doi.org/10.1016/j.jep.2014.06.034 - Avila, C., Breakspear, I., Hawrelak, J., Salmond, S. and Evans, S (2020) 'A systematic review and quality assessment of case reports of adverse events for borage (Borago officinalis), coltsfoot (Tussilago farfara) and comfrey (Symphytum officinale)', Fitoterapia, 142, pp. 104519. doi:10.1016/j.fitote.2020.104519 Meta-analysis / review
https://doi.org/10.1016/j.fitote.2020.104519 - Lee, J., Park, S., Kim, M.J., Kwon, S.J. and others (2019) 'Sesquiterpenoids from Tussilago farfara Flower Bud Extract for the Eco-Friendly Synthesis of Silver and Gold Nanoparticles Possessing Antibacterial and Anticancer Activities', Nanomaterials (Basel), 9(6), pp. 819. doi:10.3390/nano9060819 Preclinical
https://doi.org/10.3390/nano9060819 - Bota, V.B., Neamtu, A.A., Olah, N.K., Chiselita, O. and others (2022) 'A Comparative Analysis of the Anatomy, Phenolic Profile, and Antioxidant Capacity of Tussilago farfara L. Vegetative Organs', Plants (Basel), 11(13), pp. 1663. doi:10.3390/plants11131663 Preclinical
https://doi.org/10.3390/plants11131663 - Boucher, M.A., Cote, H., Pichette, A., Ripoll, L. and Legault, J (2020) 'Chemical composition and antibacterial activity of Tussilago farfara (L.) essential oil from Quebec, Canada', Natural Product Research, 34(4), pp. 545-548. doi:10.1080/14786419.2018.1489384 Preclinical
https://doi.org/10.1080/14786419.2018.1489384 - Li, Z.Y., Zhang, J., Zhang, Y.B., Yang, X.W. and others (2022) 'Polyhydroxylated eudesmane sesquiterpenoids and sesquiterpenoid glucoside from the flower buds of Tussilago farfara', Chinese Journal of Natural Medicines, 20(4), pp. 301-308. doi:10.1016/S1875-5364(21)60120-6 Preclinical
https://doi.org/10.1016/S1875-5364(21)60120-6 - Jang, H., Lee, J.W., Lee, C., Jin, Q. and others (2016) 'Sesquiterpenoids from Tussilago farfara inhibit LPS-induced nitric oxide production in macrophage RAW 264.7 cells', Archives of Pharmacal Research, 39(1), pp. 127-132. doi:10.1007/s12272-015-0667-7 Preclinical
https://doi.org/10.1007/s12272-015-0667-7 - Royal Botanic Gardens, Kew (n.d.). Available at: https://powo.science.kew.org Traditional / reference
https://powo.science.kew.org - Westendorf, J., Czok, G., Marquardt, R., Nausner, M., Krauer, B. and Paul, H.L (1988) 'Pyrrolizidine alkaloid content of Tussilago farfara plants from different regions and preparations', pp. 903--909. Traditional / reference
https://scholar.google.com/scholar?q=Pyrrolizidine%20alkaloid%20content%20of%20Tussilago%20farfara%20plants%20from%20different%20regions%20and%20preparations - European Medicines Agency (HMPC) (2021) 'Public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs), including recommendations regarding contamination of herbal medicinal products with PAs, Revision 1'. Available at: https://www.ema.europa.eu/en/documents/public-statement/public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-including-recommendations-regarding-contamination-herbal-medicinal-products-pyrrolizidine_en.pdf Traditional / reference
https://www.ema.europa.eu/en/documents/public-statement/public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-including-recommendations-regarding-contamination-herbal-medicinal-products-pyrrolizidine_en.pdf - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Sperl, W. and Stuppner, H. and Gassner, I. and Judmaier, W. and Dietze, O. and Vogel, W (1995) 'Reversible hepatic veno-occlusive disease in an infant after consumption of pyrrolizidine-containing herbal tea', European Journal of Pediatrics, 154(2), pp. 112-6. doi:10.1007/BF01991912 Clinical study
https://doi.org/10.1007/BF01991912
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.